These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 7931489

  • 1. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.
    Rowinsky EK, Adjei A, Donehower RC, Gore SD, Jones RJ, Burke PJ, Cheng YC, Grochow LB, Kaufmann SH.
    J Clin Oncol; 1994 Oct; 12(10):2193-203. PubMed ID: 7931489
    [Abstract] [Full Text] [Related]

  • 2. A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia.
    Rowinsky EK, Kaufmann SH, Baker SD, Miller CB, Sartorius SE, Bowling MK, Chen TL, Donehower RC, Gore SD.
    Clin Cancer Res; 1996 Dec; 2(12):1921-30. PubMed ID: 9816150
    [Abstract] [Full Text] [Related]

  • 3. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
    Rowinsky EK, Grochow LB, Sartorius SE, Bowling MK, Kaufmann SH, Peereboom D, Donehower RC.
    J Clin Oncol; 1996 Apr; 14(4):1224-35. PubMed ID: 8648378
    [Abstract] [Full Text] [Related]

  • 4. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.
    Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC, Kaufmann SH.
    Cancer Res; 1992 Apr 15; 52(8):2268-78. PubMed ID: 1348448
    [Abstract] [Full Text] [Related]

  • 5. Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia.
    Kantarjian HM, Beran M, Ellis A, Zwelling L, O'Brien S, Cazenave L, Koller C, Rios MB, Plunkett W, Keating MJ.
    Blood; 1993 Mar 01; 81(5):1146-51. PubMed ID: 8382970
    [Abstract] [Full Text] [Related]

  • 6. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
    Hammond LA, Eckardt JR, Ganapathi R, Burris HA, Rodriguez GA, Eckhardt SG, Rothenberg ML, Weiss GR, Kuhn JG, Hodges S, Von Hoff DD, Rowinsky EK.
    Clin Cancer Res; 1998 Jun 01; 4(6):1459-67. PubMed ID: 9626463
    [Abstract] [Full Text] [Related]

  • 7. Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study.
    Crump M, Lipton J, Hedley D, Sutton D, Shepherd F, Minden M, Stewart K, Beare S, Eisenhauer E.
    Leukemia; 1999 Mar 01; 13(3):343-7. PubMed ID: 10086724
    [Abstract] [Full Text] [Related]

  • 8. A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia.
    Gore SD, Rowinsky EK, Miller CB, Griffin C, Chen TL, Borowitz M, Donehower RC, Burks KL, Armstrong DK, Burke PJ, Grever MR, Kaufmann SH.
    Clin Cancer Res; 1998 Nov 01; 4(11):2677-89. PubMed ID: 9829730
    [Abstract] [Full Text] [Related]

  • 9. High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study.
    Rowinsky EK, Baker SD, Burks K, O'Reilly S, Donehower RC, Grochow LB.
    Ann Oncol; 1998 Feb 01; 9(2):173-80. PubMed ID: 9553662
    [Abstract] [Full Text] [Related]

  • 10. Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells.
    Kaufmann SH, Svingen PA, Gore SD, Armstrong DK, Cheng YC, Rowinsky EK.
    Blood; 1997 Mar 15; 89(6):2098-104. PubMed ID: 9058732
    [Abstract] [Full Text] [Related]

  • 11. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence.
    Rowinsky EK, Kaufmann SH, Baker SD, Grochow LB, Chen TL, Peereboom D, Bowling MK, Sartorius SE, Ettinger DS, Forastiere AA, Donehower RC.
    J Clin Oncol; 1996 Dec 15; 14(12):3074-84. PubMed ID: 8955652
    [Abstract] [Full Text] [Related]

  • 12. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia.
    Kaufmann SH, Karp JE, Jones RJ, Miller CB, Schneider E, Zwelling LA, Cowan K, Wendel K, Burke PJ.
    Blood; 1994 Jan 15; 83(2):517-30. PubMed ID: 7904487
    [Abstract] [Full Text] [Related]

  • 13. Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation.
    Lamond JP, Wang M, Kinsella TJ, Boothman DA.
    Int J Radiat Oncol Biol Phys; 1996 Sep 01; 36(2):361-8. PubMed ID: 8892461
    [Abstract] [Full Text] [Related]

  • 14. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
    Erlichman C, Boerner SA, Hallgren CG, Spieker R, Wang XY, James CD, Scheffer GL, Maliepaard M, Ross DD, Bible KC, Kaufmann SH.
    Cancer Res; 2001 Jan 15; 61(2):739-48. PubMed ID: 11212277
    [Abstract] [Full Text] [Related]

  • 15. Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study.
    Furman WL, Stewart CF, Kirstein M, Kepner JL, Bernstein ML, Kung F, Vietti TJ, Steuber CP, Becton DL, Baruchel S, Pratt C.
    J Clin Oncol; 2002 Mar 15; 20(6):1617-24. PubMed ID: 11896112
    [Abstract] [Full Text] [Related]

  • 16. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia.
    Vey N, Kantarjian H, Tran H, Beran M, O'Brien S, Bivins C, Giles F, Cortes J, Cheson B, Arbuck S, Estey E.
    Ann Oncol; 1999 May 15; 10(5):577-83. PubMed ID: 10416008
    [Abstract] [Full Text] [Related]

  • 17. Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia.
    Seiter K, Feldman EJ, Halicka HD, Traganos F, Darzynkiewicz Z, Lake D, Ahmed T.
    J Clin Oncol; 1997 Jan 15; 15(1):44-51. PubMed ID: 8996123
    [Abstract] [Full Text] [Related]

  • 18. Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia.
    Furman WL, Baker SD, Pratt CB, Rivera GK, Evans WE, Stewart CF.
    J Clin Oncol; 1996 May 15; 14(5):1504-11. PubMed ID: 8622064
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia.
    Kantarjian HM, Beran M, O'Brien S, Robertson L, Siddik Z, Yoshida M, Yang LY, Rios MB, Keating MJ, Meyer M.
    Leukemia; 1996 Mar 15; 10(3):396-401. PubMed ID: 8642853
    [Abstract] [Full Text] [Related]

  • 20. Phase I and pharmacodynamic study of taxol in refractory acute leukemias.
    Rowinsky EK, Burke PJ, Karp JE, Tucker RW, Ettinger DS, Donehower RC.
    Cancer Res; 1989 Aug 15; 49(16):4640-7. PubMed ID: 2568175
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.